Keith Moore, PHARMD
Sanotize Research and Development corp. · kmoore@sanotize.com · Xanodyne Pharmaceuticals
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Keith Moore, PHARMD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:33 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06264141 · Evaluation of Nitric Oxide Nasal Spray (NONS) for Treatment of Recurrent Acute RhinosinusitisSanotize Research and Development corp. · completed · Recurrent Acute Rhinosinusitis · study director
- Ph3NCT05599919 · Nitric Oxide Nasal Spray (NONS) To Treat and Prevent the Exacerbation of Infection in Individuals With Mild COVID-19Sanotize Research and Development corp. · completed · SARS-CoV-2 Infection · study director
- Ph3NCT05109611 · Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 InfectionSanotize Research and Development corp. · terminated · SARS-CoV-2 Infection · study director
- Ph3NCT00655291 · Efficacy of XP20B Following Bunionectomy SurgeryXanodyne Pharmaceuticals · completed · Acute Pain · unknown
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.